Developmental and Epileptic Encephalopathy 34 (DEE34) Cell Models for Research

Developmental and Epileptic Encephalopathy 34 (DEE34) is a rare genetic disorder characterized by early-onset seizures, developmental delay, and intellectual disability. The exact prevalence is unknown, but it is considered a very rare condition. According to the World Health Organization (WHO), epilepsy affects over 50 million people worldwide, but DEE34 specifically is a subset with a genetic etiology. The clinical impact is severe, with most patients experiencing refractory seizures and significant neurodevelopmental impairment. The 5-year survival is not well-defined due to rarity, but mortality is higher than in the general population, often due to complications like status epilepticus or respiratory infections. Risk factors include de novo mutations in genes such as SCN1A, GABRA1, and KCNQ2, which are critical for neuronal excitability.

DEE34 is an ideal model for studying neuronal excitability, synaptic transmission, and neurodevelopmental processes. The disease is genetically heterogeneous, with mutations in ion channel genes and neurotransmitter receptors. Public datasets, such as those in ClinVar and the Human Gene Mutation Database, provide extensive variant information. Open questions include the precise genotype-phenotype correlations and the mechanisms underlying seizure generation and developmental delay. Gene-edited cell models enable functional validation of variants and drug screening, making them invaluable for research.

While DEE34 is not a cancer, the underlying pathways are critical for neuronal function. The major pathways include:

• • Ion Channel Dysfunction: Mutations in voltage-gated sodium channels (e.g., SCN1A) and potassium channels (e.g., KCNQ2) disrupt action potential generation and propagation.
• • GABAergic Signaling: Mutations in GABA receptor subunits (e.g., GABRA1) impair inhibitory neurotransmission, leading to hyperexcitability.
• • Synaptic Vesicle Release: Mutations in genes like STXBP1 affect synaptic vesicle fusion, altering neurotransmitter release.

These pathways converge on neuronal network hyperexcitability, leading to seizures and developmental impairment.

Data from ClinVar and literature.

The deregulated networks in DEE34 include:

• • Ion Channel Complexes: Key nodes include SCN1A, SCN2A, KCNQ2, KCNQ3.
• • GABAergic Synapse: Key nodes include GABRA1, GABRB2, GABRG2.
• • Synaptic Vesicle Cycle: Key nodes include STXBP1, SYN1, SYT1.

These networks interact to maintain neuronal excitability. Disruption leads to an imbalance between excitation and inhibition.

Organoids, such as cerebral organoids, provide a 3D model with more complex neuronal networks. They can be generated from patient iPSCs and recapitulate aspects of brain development.

• • PDX (Patient-Derived Xenograft): Not applicable for DEE34 as it is not a cancer.
• • GEMM (Genetically Engineered Mouse Models): Knock-in mice carrying patient mutations (e.g., SCN1A R1648H) recapitulate seizures.
• • Induced Models: Chemoconvulsant-induced seizure models (e.g., kainic acid) are used but do not reflect genetic etiology.

CRISPR-based isogenic cell lines are powerful tools for studying DEE34. For example, a SCN1A knockout in SH-SY5Y cells can model loss-of-function, while a knock-in of a specific mutation (e.g., SCN1A c.4936C>T) can model a patient variant. These models are sequence-verified and commercially available, accelerating research. They allow precise control of genetic background, enabling functional studies and drug screening.

Knockout and knock-in lines validate the pathogenicity of variants. For example, a GABRA1 knockout line shows reduced GABAergic currents, confirming its role. Such models are used to study gene function and identify interacting partners.

Isogenic pairs (wild-type vs. mutant) are used to screen for compounds that rescue the phenotype. For instance, a KCNQ2 mutant line can be used to test potassium channel openers. Resistance to antiseizure drugs can be modeled by exposing cells to drugs and selecting resistant clones.

CRISPR synthetic lethality screens can identify genes that, when knocked out, are lethal only in mutant cells. This can reveal novel therapeutic targets. For example, in SCN1A mutant cells, a screen might identify genes involved in compensatory pathways.